Cargando…
Incidental finding of non-alcoholic steatohepatitis-cirrhosis
SUMMARY: A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease. The patient was followed at a gastroenterology department due to Crohn’s disease and post-operat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875068/ https://www.ncbi.nlm.nih.gov/pubmed/36571477 http://dx.doi.org/10.1530/EDM-22-0350 |
_version_ | 1784877880497405952 |
---|---|
author | Adrian, Therese Hornum, Mads Knop, Filip Krag Lotte Gluud, Lise |
author_facet | Adrian, Therese Hornum, Mads Knop, Filip Krag Lotte Gluud, Lise |
author_sort | Adrian, Therese |
collection | PubMed |
description | SUMMARY: A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease. The patient was followed at a gastroenterology department due to Crohn’s disease and post-operative bile acid malabsorption. The patient had no symptoms or biochemical findings suggesting liver disease. Surprisingly, a transient elastography (FibroScan(®)) suggested advanced fibrosis with a median of 16.1 kPa. A liver biopsy showed non-alcoholic steatohepatitis (NASH)-cirrhosis. The diagnosis was only made incidentally and highlights how NASH-cirrhosis may be overlooked due to the lack of symptoms. LEARNING POINTS: Clinicians treating high-risk populations, including patients with type 2 diabetes and/or components of the metabolic syndrome, should be aware of the frequently occurring co-existence with non-alcoholic fatty liver disease (NAFLD) and especially non-alcoholic steatohepatitis (NASH). Liver enzymes may be in the normal range even in people with steatosis, NASH, or even cirrhosis. The diagnosis of NAFLD should include evaluation of hepatic fibrosis as this is the most important prognostic factor for liver-related complications and mortality. Guidelines about systematic screening for NAFLD in patients with type 2 diabetes are incongruent. |
format | Online Article Text |
id | pubmed-9875068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-98750682023-02-06 Incidental finding of non-alcoholic steatohepatitis-cirrhosis Adrian, Therese Hornum, Mads Knop, Filip Krag Lotte Gluud, Lise Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease SUMMARY: A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease. The patient was followed at a gastroenterology department due to Crohn’s disease and post-operative bile acid malabsorption. The patient had no symptoms or biochemical findings suggesting liver disease. Surprisingly, a transient elastography (FibroScan(®)) suggested advanced fibrosis with a median of 16.1 kPa. A liver biopsy showed non-alcoholic steatohepatitis (NASH)-cirrhosis. The diagnosis was only made incidentally and highlights how NASH-cirrhosis may be overlooked due to the lack of symptoms. LEARNING POINTS: Clinicians treating high-risk populations, including patients with type 2 diabetes and/or components of the metabolic syndrome, should be aware of the frequently occurring co-existence with non-alcoholic fatty liver disease (NAFLD) and especially non-alcoholic steatohepatitis (NASH). Liver enzymes may be in the normal range even in people with steatosis, NASH, or even cirrhosis. The diagnosis of NAFLD should include evaluation of hepatic fibrosis as this is the most important prognostic factor for liver-related complications and mortality. Guidelines about systematic screening for NAFLD in patients with type 2 diabetes are incongruent. Bioscientifica Ltd 2022-12-06 /pmc/articles/PMC9875068/ /pubmed/36571477 http://dx.doi.org/10.1530/EDM-22-0350 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Unique/Unexpected Symptoms or Presentations of a Disease Adrian, Therese Hornum, Mads Knop, Filip Krag Lotte Gluud, Lise Incidental finding of non-alcoholic steatohepatitis-cirrhosis |
title | Incidental finding of non-alcoholic steatohepatitis-cirrhosis |
title_full | Incidental finding of non-alcoholic steatohepatitis-cirrhosis |
title_fullStr | Incidental finding of non-alcoholic steatohepatitis-cirrhosis |
title_full_unstemmed | Incidental finding of non-alcoholic steatohepatitis-cirrhosis |
title_short | Incidental finding of non-alcoholic steatohepatitis-cirrhosis |
title_sort | incidental finding of non-alcoholic steatohepatitis-cirrhosis |
topic | Unique/Unexpected Symptoms or Presentations of a Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875068/ https://www.ncbi.nlm.nih.gov/pubmed/36571477 http://dx.doi.org/10.1530/EDM-22-0350 |
work_keys_str_mv | AT adriantherese incidentalfindingofnonalcoholicsteatohepatitiscirrhosis AT hornummads incidentalfindingofnonalcoholicsteatohepatitiscirrhosis AT knopfilipkrag incidentalfindingofnonalcoholicsteatohepatitiscirrhosis AT lottegluudlise incidentalfindingofnonalcoholicsteatohepatitiscirrhosis |